Cardiology Search
Cardiology Cardiology
venous%20thromboembolism%20-%20management
VENOUS THROMBOEMBOLISM - MANAGEMENT
Deep vein thrombosis is a frequent manifestation of venous thromboembolism in which there is a blood clot blocking a deep vein.
Clinical findings are important to the diagnosis of deep vein thrombosis but are poor predictors of the presence or severity of thrombosis.
Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially veins in the legs and pelvis.
Dyspnea, pleuritic chest pain, syncope and tachypnea occur in most cases of pulmonary embolism.
Massive pulmonary embolism has the prime symptom of dyspnea and systemic arterial hypotension, that requires pressor support, is the predominant sign.

Venous Thromboembolism - Management Drug Information

Drug Information

Indication: DVT & pulmonary embolism (PE). Prevention of stroke & systemic embolism in adult patients w/ non-valvu...

Indication: Thrombolytic treatment in acute MI, acute massive pulmonary embolism w/ haemodynamic instability & of acut...

Indication: 2.5 mg: Prevention of venous thromboembolic events (VTE) in patients undergoing major orthopaedic lower limbs ...

Cardin
aspirin + glycine

Indication: Transient ischaemic attacks, secondary prevention of MI. Prophylaxis against stroke, vascular occlusion & ...

Indication: Transient ischaemic attacks, secondary prevention of MI. Platelet aggregation inhibitor for prophylaxis agains...

Indication: AMI. Prevention of heart attack in certain high-risk patients; prevention of CVA after transient ischaemic att...

Indication: Prophylaxis & treatment of venous thrombosis & pulmonary embolism. MI & arterial embolism. Prevent...

Indication: Vascular pathologies w/ thrombotic risk.

Wincardia
aspirin + glycine

Indication: Transient ischaemic attacks, secondary prevention of MI. Prophylaxis against stroke, vascular occlusion & ...

Indication: 10-mg tab Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replace...

1  /  2
1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Finerenone reduces CKD progression, CV risk
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.